CTOs on the Move

ProCare Rx

www.procarerx.com

 
ProCare Rx is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.procarerx.com
  • 3090 Premiere Pkwy Ste 100
    Duluth, GA USA 30097
  • Phone: 678.248.3105

Executives

Name Title Contact Details

Similar Companies

Otter House Wellness

Find quality addiction treatment in North Carolina, where you’ll experience the care, flexibility, and support you need to conquer substance use.

HCA Midwest Health System

HCA Midwest offers a superior level of medical care with 12 state-of-the-art diagnostic and treatment facilities providing a broad range of emergency, outpatient and wellness services as well as acute- and post-acute care.

HealthFirst Third Party Administrators

HealthFirst Third Party Administrators is a Tyler, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Providence and LogistiCare

The Providence Service Corporation, through its fully-owned subsidiary LogistiCare Solutions, LLC, is the nation`s largest manager of non-emergency medical transportation programs for state governments and managed care organizations. Its range of services includes call center management, network credentialing, vendor payment management and non-emergency medical transport management. The Company also holds a minority interest in Matrix Medical Network which provides a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.